{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:55:37Z","timestamp":1793811337032,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073818"],"award-info":[{"award-number":["82073818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12325-022-02273-4","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T08:02:38Z","timestamp":1660032158000},"page":"4583-4593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA"],"prefix":"10.1007","volume":"39","author":[{"given":"Jingyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"6","key":"2273_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"2273_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14737167.2021.1848553","volume":"21","author":"V Diaby","year":"2021","unstructured":"Diaby V, Almutairi RD, Babcock A, Moussa RK, Ali A. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):353\u201364.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"2273_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"key":"2273_CR5","unstructured":"National Comprehensive Cancer Network. Breast cancer, version 1.2021. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 10 Apr 2022."},{"issue":"19","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"7","key":"2273_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-010-0764-8","volume":"123","author":"ML Kwan","year":"2010","unstructured":"Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study. Breast Cancer Res Treat. 2010;123(2):507\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2273_CR9","first-page":"473","volume":"146","author":"A Laupacis","year":"1992","unstructured":"Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473\u201381.","journal-title":"CMAJ"},{"issue":"1","key":"2273_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","volume":"12","author":"CP Lee","year":"2009","unstructured":"Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80\u20137.","journal-title":"Value Health"},{"issue":"9","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/027298902320556118","volume":"22","author":"WC Winkelmayer","year":"2002","unstructured":"Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5):417\u201330.","journal-title":"Med Decis Making"},{"key":"2273_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"2273_CR14","unstructured":"U.S. Bureau of Labor Statistics. Calculators. 2022. https:\/\/www.bls.gov\/data\/inflationcalculator.htm. Accessed 10 Apr 2022."},{"key":"2273_CR15","unstructured":"National Hospice and Palliative Care Organization. 2014 National summary of hospice care. 2022. https:\/\/www.nhpco.org\/archived-national-summary-reports\/. Accessed 9 Jul 2022."},{"key":"2273_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3389\/fonc.2020.01336","volume":"10","author":"Q Wu","year":"2020","unstructured":"Wu Q, Liao W, Zhang M, Huang J, Zhang P, Li Q. Cost-effectiveness of tucatinib in human epidermal growth factor receptor 2-positive metastatic breast cancer from the US and Chinese perspectives. Front Oncol. 2020;10:1336.","journal-title":"Front Oncol"},{"issue":"11","key":"2273_CR17","doi-asserted-by":"publisher","first-page":"11382","DOI":"10.21037\/apm-21-2412","volume":"10","author":"H Wang","year":"2021","unstructured":"Wang H, Wang Y, Gong R, Geng Y, Li L. Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China. Ann Palliat Med. 2021;10(11):11382\u201393.","journal-title":"Ann Palliat Med"},{"issue":"10","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"2273_CR19","unstructured":"CMS.gov (Centers for Medicare & Medicaid Services). Hospice. 2022. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/Hospice. Accessed 9 Jul 2022."},{"issue":"1","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","volume":"9","author":"CL Arteaga","year":"2011","unstructured":"Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9(1):16\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"2273_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1471-2407-12-165","volume":"12","author":"M John","year":"2012","unstructured":"John M, Hinke A, Stauch M, et al. Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines\u2013a phase II multipractice study. BMC Cancer. 2012;12:165.","journal-title":"BMC Cancer"},{"issue":"16","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMp1007168","volume":"363","author":"PJ Neumann","year":"2010","unstructured":"Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010;363(16):1495\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"2273_CR23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2015.3316","volume":"1","author":"DA Goldstein","year":"2015","unstructured":"Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol. 2015;1(9):1293\u2013300.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2273_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-016-3978-6","volume":"160","author":"V Diaby","year":"2016","unstructured":"Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160(1):187\u201396.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COC.0000000000000816","volume":"44","author":"J Sussell","year":"2021","unstructured":"Sussell J, Singh Jhuti G, Antao V, Herrera-Restrepo O, Wehler E, Bilir SP. Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States. Am J Clin Oncol. 2021;44(7):340\u20139.","journal-title":"Am J Clin Oncol"},{"key":"2273_CR26","unstructured":"CMS.gov (Centers for Medicare & Medicaid Services). 2022 ASP drug pricing files. 2022. https:\/\/www.cms.gov\/files\/zip\/april-2022-asp-pricing-file.zip. Accessed 24 Apr 2022."},{"key":"2273_CR27","unstructured":"Drugs.com. Prices, coupons and patient assistance programs. 2022. https:\/\/www.drugs.com\/price-guide\/. Accessed 10 Apr 2022."},{"key":"2273_CR28","unstructured":"CMS.gov (Centers for Medicare & Medicaid Services). Medicare physician fee schedule. 2022. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx. Accessed 9 Apr 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02273-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:10:15Z","timestamp":1662948615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02273-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02273-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}